UnicoCell focuses on the research of allogeneic stem cells and new drug developments. UnicoCell’s investigational treatment, ELIXCYTE (allogeneic adipose-derived stem Cells), has completed a Phase 1/2 trial of Chronic Kidney Disease. We are conducting clinical trials to obtain regulatory approval to make ELIXCYTE available to all patients as quickly as possible. ELIXCYTE shows highly potential in disease treatments, which is one of very few regenerating medicines for CKD therapy. As such, we believe participation in our clinical trials is the most appropriate way to access ELIXCYTE at this stage of development. Information about our clinical trials, including eligibility criteria and locations, is available at clinicaltrials.gov.
Unicocell understands patients' interest in accessing ELIXCYTE outside of clinical trials and prior to regulatory approval for CKD; however, we do not currently offer any Expanded Access Programs for ELIXCYTE.
Unicocell recognizes the need for Expanded Access Programs and will re-evaluate the status of our policy based on data from ongoing and future clinical trials.